Both Novo and obesity market rival Eli Lilly have outlaid significant funds to ensure future demand for oral weight loss drugs is met.

But here’s the rub. Not only should the fact that an American company is paying twice as much tax in Ireland as it does in America, where the revenue is generated, annoy all Americans, but the money ...

Apple, more than any other company, catalysed the smartphone revolution, inadvertently placing Ireland at the centre of it. The State might be about to ride another technology gear change, this time ...

Exclusive reporting on Munster, national and international business news and how it impacts Ireland and the poeple who live ...

The market for weight-loss drugs is booming - but the pioneer in the field is shedding profits and share value, writes Adam Maguire ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A local contractor is completing the buildout of a new manufacturing line in an existing Lilly building that focuses on ...

A local contractor is completing the buildout of a new manufacturing line in an existing Lilly building that focuses on ...

Eli Lilly posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The ...

Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss. But it's also proving innovative even beyond its core ...

This history of rapid acceleration suggests that Eli Lilly is primed for another massive breakout as new catalysts emerge.